What results does 0.5mg semaglutide actually produce?

What the STEP trials tell us about early doses

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and at least one weight-related condition. Participants received weekly semaglutide injections, titrated upward over 16 weeks, before settling at the 2.4mg maintenance dose for the remainder of the 68-week study. The headline finding (roughly 15% average body-weight reduction) reflected the full course, not any single dose along the way.

This matters for understanding 0.5mg results specifically. By the time someone is injecting 0.5mg each week, they have usually spent the first four weeks at 0.25mg and are moving through what the licensed schedule describes as a tolerability phase. The medicine is active, appetite suppression begins, and some people notice early changes in hunger. But the body is still adapting to the drug's mechanism, slowing gastric emptying, increasing feelings of fullness via GLP-1 receptor activity. Measurable weight change at this stage is real but modest compared with what accumulates over months. The NHS semaglutide medicines page reflects this: the early doses are there to reduce the likelihood of gastrointestinal side effects, not to deliver the final therapeutic effect.

For a broader picture of how the full dose ladder is structured, the guide to Wegovy's dose schedule covers each step and what to expect at each stage.

Why results vary so much between people at this dose

Two people on 0.5mg semaglutide in the same week may have very different experiences. One might notice a meaningful reduction in appetite within days; another may feel little change yet. Several factors shape early response: how quickly GI side effects settle, whether a person is eating and moving alongside treatment as the licence requires, and individual differences in how the GLP-1 pathway is expressed. Weight lost during the 0.5mg phase often includes an initial drop that partly reflects reduced food volume rather than sustained fat loss, the kind of change that consolidates as the dose increases.

There is also the question of what people are comparing against. Someone who has been on a very low-calorie diet for weeks before starting semaglutide may see little additional change at 0.5mg; someone who was eating well above their energy needs may notice more. Neither scenario means the medicine is or is not working, it means the 0.5mg stage is a starting point, not the destination. For a closer look at what wegovy 0.5 mg results tend to show in practice, the evidence gives a clearer sense of what is typical at this early stage. Research into whether semaglutide affects energy expenditure beyond appetite alone adds useful context here, because the mechanisms extend further than simply eating less.

The titration schedule exists precisely because individual tolerance varies. Rushing through early doses to reach a higher one quickly is a clinical decision, not a self-management one. Staying at 0.5mg longer than four weeks is sometimes appropriate; so is progressing on schedule. That call belongs with the prescriber.

What to expect as the dose increases beyond 0.5mg

The licensed Wegovy titration moves from 0.25mg to 0.5mg, then to 1mg, 1.7mg and finally 2.4mg, each step roughly four weeks apart under prescriber review. The cumulative evidence from STEP 1 shows weight reduction tends to accelerate as the maintenance dose is reached and sustained. Early phases contribute to the overall trajectory even when the number on the scale moves slowly.

For people curious about how results evolve: the evidence at the 2.4mg maintenance dose and the picture at 1mg both offer comparison points grounded in the same trial programme. The STEP 1 paper itself is the anchor for those figures. Looking at results in isolation (one dose, one week) rarely tells the full story.

On the question of cost, the cost of Wegovy in the UK page sets out what private treatment realistically involves at each stage, without inflating or minimising the numbers.

Side effects at 0.5mg and how they relate to results

Gastrointestinal symptoms (nausea, loose stools, an unsettled stomach) are most commonly reported in the weeks after a dose change. The step from 0.25mg to 0.5mg is one of those moments, and for some people it is the first time the medicine really registers physically. Most symptoms are mild to moderate and ease within a fortnight as the body adjusts.

The MHRA advises reporting suspected side effects through the Yellow Card scheme, and anyone experiencing severe, persistent stomach pain that spreads to the back should seek medical attention promptly, this can occasionally indicate pancreatitis, a known but uncommon risk with GLP-1 medicines. Staying hydrated helps if nausea reduces appetite to the point of eating very little; protein foods are worth prioritising at meals even when portions are smaller.

None of this is unique to 0.5mg, similar patterns appear at each titration step. The dose happens to be the one many people are at when they first notice the medicine's effects clearly, which is why questions about results at this stage are so common. If you are finding the 0.5mg step difficult, or want to understand whether your response so far is typical, that is exactly the kind of question a prescriber is there to answer. Starting a free consultation is the first step.